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ABSTRACT 
Our aim was to investigate the impact of a baseline New York Heart Association (NYHA) class IV 
on clinical outcomes of a large real-world population undergoing TAVI. The primary end-points 
were all-cause mortality, cardiovascular mortality and re-hospitalization, evaluated at the longest 
available follow-up and by means of a 3-month Landmark analysis. The secondary end-points were: 
change in NYHA class, left ventricular ejection fraction, pulmonary pressure and mitral 
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regurgitation. Out 2,467 patients, 271 (11%) had a NYHA functional class IV at the admission. The 
latter had higher STS score (9.2% vs. 5.5%; p<0.001) compared to NYHA ≤III patients, owing to 
more comorbidities (prior myocardial infarction, severe chronic kidney disease, atrial fibrillation, 
left ventricular dysfunction, significant mitral regurgitation, pulmonary hypertension). Device 
success was similar between the two groups (93.7% vs. 94.5%; p=0.583). At a median follow-up of 
15 months (IQR 4-36 months) a lower freedom from primary end-points was observed among 
NYHA IV vs. NYHA ≤III group (survival from all-cause death: 52% vs. 58.4%; p=0.002; survival 
from cardiovascular death: 72.5% vs. 76.5%; p=0.091; freedom from re-hospitalization: 81.5% vs. 
85.4%; p=0.038). However, after adjustment for baseline imbalance, NYHA IV did not influence 
the relative risk of long-term primary end-points. A 3-month Landmark analysis showed that 
NYHA IV independently predicted 3-month all-cause and cardiovascular mortality (HR: 1.77; 95% 
CI [1.10-2.83]; p=0.018 and HR: 1.64; 95% CI [1.03-2.59]; p=0.036, respectively). Instead, after 3-
month follow-up NYHA IV did not affect the risk of primary end-points. A significant 
improvement of the secondary end-points was noted in both NYHA IV and NYHA ≤III groups. 
In conclusion, the presence of NYHA class IV in TAVI candidates was associated to a significant 
increased risk of mortality within 3 months. Patients with baseline NYHA IV who survived at 3 
months had a long-term outcome comparable to that of other subjects. Left ventricular systolic 
function, pulmonary pressure and mitral insufficiency significantly improved after TAVI regardless 
of the presence of NYHA class IV.  
Key words: NYHA class IV, TAVI, mortality, re-hospitalization 
Introduction  
Transcatheter aortic valve implantation (TAVI) is by now a well-established therapy for patients 
with severe and symptomatic aortic stenosis at intermediate, high or prohibitive surgical risk1-6. 
Non-randomized data showed safety and efficacy of TAVI also in patients with severe pure aortic 
regurgitation and failed surgical bioprosthesis who cannot deal with redo7-9. TAVI has been shown 
to improve survival, quality of life and functional status. In particular, a significant reduction of 
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New York Heart Association (NYHA) class at early and long-term follow-up has been previously 
and consistently reported in TAVI recipients10,11.  
However, limited evidence is available on prognostic significance of a baseline advanced functional 
NYHA class 12,13 and specific data on the presence of NYHA class IV at the admission in TAVI 
candidates are lacking. We sought to explore the impact of a baseline NYHA functional class IV on 
clinical outcomes of a large real-world population undergoing first and second generation of 
Medtronic self-expanding bioprosthesis implantation. 
Methods  
Between June 2007 and September 2017, all consecutive patients undergoing TAVI with 
either Medtronic CoreValve or Evolut R system were prospectively included in the Italian 
ClinicalService® Project (Clinical Trial Registration NCT01007474). This is an ongoing nation-
based clinical data repository and medical care project aimed at describing and improving the use of 
implantable devices in Italian clinical practice already described elsewhere14. The project was 
approved by each site’s Institutional Review Board or Medical Director and conforms to the 
principles outlined in the Declaration of Helsinki. Each patient provided an informed consent for 
data collection and analysis. 
According to the current recommendations, eligibility for TAVI was established at each 
centre based on the consensus of a local multidisciplinary team (including cardiologists, cardiac 
surgeons and anaesthesiologists) that took into account the individual calculated risk of surgery, 
comorbidity or conditions not included into the scores, patient’s frailty and the technical feasibility 
of TAVI. Clinical and echocardiographic follow-up were performed at 30 days, 1 year and then 
yearly with visits or telephone contacts according to each centre’s clinical practice.  
For the purpose of the current analysis, all consecutive patients whose baseline NYHA class was 
available were included. The study population was divided in two groups according to the presence 
of NYHA class IV or NYHA class ≤III at the admission. NYHA class IV was defined as the 
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presence of dyspnoea even at rest and inability to carry on any physical activity without discomfort 
and worsening of symptoms. 
The primary endpoints, defined according to the VARC-2 recommendations, were: all-cause 
death, cardiovascular death and re-hospitalization due to valve-related symptoms or heart failure15.    
These endpoints have been stratified by the presence of NYHA class IV at the admission and 
evaluated at longest follow-up and by means of a Landmarks analysis with a cut-off of 3 months. 
The 3-month cut-off was assessed by visual estimation of the Kaplan Meier plots, identifying the 
point where the two curves started to get parallels.  
The secondary end-points were the change in NYHA class after TAVI and the variations over time 
(baseline, discharge, 30-day and 1-year) of echocardiographic parameters (i.e. ejection fraction, 
pulmonary pressure and mitral regurgitation) in NYHA IV versus NYHA ≤III groups.  
Continuous variables were reported as mean and standard deviation (SD) or median and 
interquartile range (IQR). Categorical variables are reported as count and percentage. Comparisons 
between groups have been performed using Wilcoxon’s Test for continuous variables, while 
comparisons of categorical variables have been performed by means of Chi-square test or Fisher 
exact test for extreme proportions, as appropriate. To compare variables over time, a repeated 
measure model or the McNemar test have been performed, as appropriate.  
The analyses of time-to-the-first event for the primary endpoints were described by means of 
Kaplan-Meier curves and long-rank test after testing proportional hazard hypothesis. A Landmark 
analysis for mortality and cardiovascular mortality at 3 months was performed, showing Kaplan 
Meier curves and survival probabilities. Baseline variables differently distributed at an alpha level 
of 0.10  (age, BMI, hypertension, prior MI, haemoglobin, severe chronic kidney disease, history of 
atrial fibrillation, significant aortic regurgitation, significant mitral regurgitation, ejection fraction 
and severe pulmonary hypertension) were entered in a stepwise Cox regression model in order to 
calculate the adjusted relative risk of primary endpoints. Each result was expressed as hazard ratio 
(HR) and corresponding 95% confidence interval (CI). Statistical tests were based on a two-sided 
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significance level of 0.05. The SAS software, version 9.4, (SAS Institute Inc., Cary, NC, USA) was 
used to perform statistical analyses. 
Results 
Among 2,467 patients included in the present study, 271 subjects (11%) had a NYHA 
functional class IV at the admission.  
Baseline characteristics according to the presence of NYHA class IV are reported in Table 1. 
Compared to patients presenting a NYHA class ≤III, those with NYHA class IV at the admission 
were more likely to have prior myocardial infarction, severe chronic kidney disease, history of atrial 
fibrillation, left ventricular dysfunction, significant mitral regurgitation and severe pulmonary 
hypertension. Moreover, NYHA IV population more frequently underwent TAVI due to pure aortic 
regurgitation or surgical bioprosthesis degeneration compared to NYHA ≤III group. As expected, 
NYHA IV patients had higher calculated surgical risk scores. 
Procedural data stratified by the presence of NYHA class IV at the admission are shown in 
Table 2. Femoral approach was less common among patients with NYHA IV vs. NYHA≤ III. 
General anaesthesia was more frequently used in NYHA IV compared with NYHA ≤ III patients 
with consequently longer procedural time, but similar fluoroscopy time and contrast amount. 
Predilation was less frequently performed in NYHA IV vs. NYHA ≤ III group, whereas postdilation 
was more commonly carried out among NYHA IV patients. Device success was similar between 
the two groups. 
In hospital all-cause and cardiovascular mortality were significantly higher in NYHA IV 
group compared with NYHA ≤ III patients (7.7% vs. 3.4%; p<0.001 and 5.9% vs. 3.3%; p=0.028 
respectively). No differences were observed between the two groups with respect to bleeding 
events, vascular complications, AKI occurrence, need for new pacemaker and paravalvular leak rate 
at the discharge. Hospital length was significantly higher in NYHA IV as compared to the control 
group (Table 3).  
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At 30 day follow-up an increased all-cause mortality rate was observed in NYHA IV vs. NYHA ≤ 
III group (8.9% vs. 5%; p=0.008). No differences were noted between the two groups with respect 
to cardiovascular mortality, stroke/TIA, myocardial infarction, re-hospitalization, need for new 
pacemaker and significant paravalvular leak (Table 3). 
After a median follow up of 15 months (IQR 4-36 months) a significant lower survival free 
from all-cause death was noted among patients with NYHA IV as compared to NYHA ≤ III group 
(52% vs. 58.4%; p=0.002) (Figure 1A). A statistically non-significant trend towards a lower 
cardiovascular survival rate was observed in NYHA IV patients compared with the control group 
(72.5% vs. 76.5%; p=0.091) (Figure 1B). Survival free from re-hospitalization was significantly 
lower in NYHA IV patients as compared to NYHA ≤ III group (81.5% vs. 85.4%; p=0.038) 
(Figure 1C). 
After adjustment for the baseline imbalance, the presence of NYHA class IV at the admission did 
not modify the relative risk of long-term all-cause death (HR: 1.07; 95%CI [0.78-1.48]; p=0.670), 
cardiovascular mortality (HR 0.97; 95%CI [0.62-1.53]; p=0.909) and re-hospitalization (HR 0.97; 
95% CI [0.53 – 1.80]; p=0.940). 
Within 3 months after TAVI, significantly lower rates of survival free from all-cause death 
(83.3% vs. 91.3%; p<0.001), cardiovascular mortality (89.6% vs. 93.6%; p=0.016) and re-
hospitalization (93.9% vs. 96.6%; p=0.038) were observed in patients with NYHA IV at the 
admission as compared to patients with baseline NYHA class ≤ III (Figure 2A, 2B and 2C).  
Baseline NYHA class IV was associated with an increased adjusted relative risk of all-cause death 
(HR: 1.77; 95% CI [1.10-2.83]; p=0.018) and cardiovascular death (HR: 1.64; 95% CI [1.03-2.59]; 
p=0.036) within 3-month follow-up. However, the adjusted relative risk of re-hospitalization within 
3-month is not affected by the presence of NYHA class IV at the baseline (HR: 1.33; 95% CI [0.67-
2.64]; p=0.415).   
Since 3-month time-point survival free from all-cause death, cardiovascular death and re-
hospitalization did not differ between the two groups (NYHA IV vs. NYHA ≤ III group: 62.4% vs. 
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63.9%; p=0.430; 80.9% vs. 81.7%;p=0.960; 86.7% vs. 88.4%; p=0.280, respectively) (Figure 2D, 
2E and 2F) and the adjusted risk of primary endpoints was not affected by baseline functional 
status (all-cause death: HR: 0.86; 95%CI [0.58-1.26]; p=0.440; cardiovascular death: HR: 0.63; 
95% CI [0.33 - 1.19];p=0.157; re-hospitalization: HR: 0.78; 95% CI [0.40 - 1.51]; p=0.461).  
NYHA class significantly improved during the follow-up in the overall population 
(P<0.001). Among patients with NYHA IV at the baseline, only 4.7% had persistence of NYHA IV 
at 30 days and none had NYHA IV at 1-year.  
Mean left ventricular ejection fraction significantly increased from baseline up to 1-year 
follow-up in both NYHA IV and ≤III groups (both p<0.001) with values that were significantly 
lower in NYHA IV vs. NYHA ≤III group at baseline (45±14% vs. 52±12%; p<0.001), discharge 
(47±12% vs. 53±10%; p<0.001) and 30-day (49±12% vs. 54±10%; p<0.001), but reaching 
similarity at 1-year follow-up (53±12% vs. 56±9%; p=0.166) (Figure 3A). 
Mean systolic pulmonary pressure and mitral regurgitation also significantly improved from 
baseline to discharge (both p <0.001), 30-day (both p <0.001) and 1-year (both p <0.001) follow-up 
in both groups (Figure 3B and 3C). Pulmonary pressure level was comparable in NYHA IV and 
NYHA ≤III groups since discharge up to 1-year time-point (discharge: 40± 12 mmHg vs. 38± 12 
mmHg; p=0.095 – 30-day: 40± 13 mmHg vs. 38± 10 mmHg; p=0.166 – 1-year: 39± 13 vs. 38± 10 
mmHg; p=0.516) (Figure 3B). Also mitral regurgitation degree was similar in NYHA IV and ≤III 
populations at discharge (p=0.138), 30-day (p=0.138) and 1-year (p=0.874) follow-up (Figure 3C).  
Discussion 
The main findings of the present study can be summarized as follows: i) NYHA class IV at the 
admission was independently associated to an increased risk of all-cause and cardiovascular 
mortality within 3 months after TAVI; ii) Patients with baseline NYHA IV who survived at 3-
month follow-up had a long-term prognosis comparable to that of patients with NYHA class ≤III; 
iii) Left ventricle systolic function, systolic pulmonary pressure and mitral regurgitation 
significantly improve after TAVI regardless of baseline NYHA IV class. 
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Previous studies including TAVI populations often reported NYHA functional classes III and IV as 
a single entity. In PARTNER cohorts more than 90% of high- or extreme-risk patients and almost 
80% of intermediate-risk patients had NYHA class III or IV at the admission. In European and 
American registries the rate of advanced NYHA class (III or IV) ranges from 75% to 91%10,16. An 
advanced functional status (NYHA III or IV) has been previously reported as predictor of adverse 
prognosis at early and mid-term follow-up after TAVI12,13. 
However, patients with severe aortic valve disease and NYHA class IV are highly different from 
others. They suffer from symptoms at rest and are definitely more clinically compromised than 
those with NYHA class ≤III. They are not electively admitted for TAVI but due to acute heart 
failure or pulmonary edema, often as first and dramatic manifestation of their aortic valve disease, 
sometimes requiring a definitive intervention to allow discharge.  
The incidence of baseline NYHA class IV in our population (11%) is consistent with that reported 
in previous studies that separately showed baseline NYHA class IV data (5% to 20%)4,6,12,13,17. 
Nevertheless, current evidence regarding the prognostic role of baseline NYHA class IV on clinical 
outcome after TAVI is very limited and specific considerations on the presence of symptoms at rest 
in patients with severe aortic valve disease undergoing TAVI are lacking.  
In our population, the higher mortality and re-hospitalization rate at long-term follow-up in NYHA 
IV compared with NYHA ≤III group was owed to the presence of more comorbidity. A high-risk 
profile (STS >8%) was observed in almost two-third of NYHA IV population due to a higher 
incidence of prior myocardial infarction, atrial fibrillation, severe chronic kidney disease, 
significant mitral regurgitation, left ventricular dysfunction and severe pulmonary hypertension.  
Indeed, after adjustment for these baseline imbalances, NYHA class IV did not influence the risk of 
long-term adverse events.  
Nevertheless, a Landmark analysis showed that survival free from primary end-points at 3-month 
was lower in NYHA IV vs. NYHA ≤III within 3-month follow-up. NYHA IV resulted as 
independent predictor of 3-month all-cause and cardiovascular mortality increasing the relative risk 
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of 77% and 64%, respectively. Therefore, in TAVI candidates, the presence of symptoms at rest, 
may affect early-term prognosis. This result is expectable given that, as mentioned above, patients 
in NYHA class IV are basically admitted due to acute heart failure rather than for elective TAVI. 
Importantly, patients with NYHA class IV who undergo TAVI and survive at 3-month follow-up 
have a clinical outcome comparable to that of subjects with NYHA ≤III class.  
Roughly one half of patients with severe aortic stenosis do not report symptoms18. Effort symptoms 
are difficult to be assessed in elderly populations with aortic disease because of a common 
inclination to restrict daily activities in order to avoid symptoms rather than complain about their 
difficult conditions. Often, these patients reach our attention when advanced and no longer self-
controllable symptoms (at rest – NYHA IV) occur. American and European guidelines19,20 state that 
asymptomatic patients with severe aortic stenosis should be followed with a watchful waiting 
strategy unless of left ventricular dysfunction, abnormal exercise stress test, very severe aortic 
stenosis, rapid progression of the disease, severe pulmonary hypertension or high level of 
neurohormones. However, these observations are based on non-randomized trials including surgery 
candidates. Similarly, our efforts should be pointed towards an early identification of symptoms in 
TAVI candidates, avoiding development of NYHA class IV and offering to these patients an early 
treatment that might improve early-term survival. The ongoing Evaluation of Transcatheter Aortic 
Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic 
Stenosis (EARLY TAVR) study (NCT03042104) will definitely shed light on this interesting issue.  
Previous evidence consistently reported early and persistent improvement of left ventricular systolic 
function, pulmonary hypertension and mitral insufficiency in patients with severe aortic stenosis 
undergoing TAVI owed to afterload abolition21-25. We confirm these findings in a more complex 
population, including patients with bioprosthesis degeneration and pure aortic regurgitation, and 
regardless of baseline NYHA class IV. Indeed, left ventricular ejection fraction, systolic pulmonary 
pressure and mitral regurgitation degree, which are worse in NYHA IV vs. ≤III group at baseline, 
significantly improve up to 1-year follow-up in both groups.  
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Of note, pulmonary pressure level and mitral regurgitation degree of NYHA IV patients reached 
values similar to that of NYHA ≤III subjects at discharge. Whereas left ventricular ejection fraction 
progressively improved in NYHA IV group reaching levels comparable to NYHA ≤III patients at 1-
year follow-up. A slower recovery of left ventricular systolic function in a particularly 
compromised population could be reasonable.  
Our study has several main limitations. First, the non-randomized design and the consequent 
presence of possible confounding factors that could have influenced our results; however, the 
inclusion of consecutive patients and the statistical adjustment for baseline imbalance should have 
minimized potential selection bias. Second, the absence of an independent monitoring with external 
adjudication of the events might limit the strength of the present analysis. Third, echocardiographic 
data have not been analysed by an independent core laboratory, but by dedicated and highly 
experienced physicians at each centre. Fourth, data on left ventricular diastolic function, which has 
been previously shown to be associated with NYHA improvement after TAVI26, are missing.  
In conclusion, in TAVI candidates, a NYHA class IV at the admission was associated to an almost 
80% increased risk of all-cause mortality and to a more than 60% increased risk of cardiovascular 
mortality within 3 months after the procedure compared to NYHA ≤III. However, after this time-
point, the mortality risk was comparable between patients with baseline NYHA IV and NYHA ≤III 
class. A significant improvement of left ventricular systolic function, pulmonary pressure and mitral 
regurgitation after TAVI was observed regardless of NYHA IV class at the admission. 
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Figure 1. Kaplan Meyer curves of all-cause death (a), cardiovascular death (b) and readmission (c) 
up to 4-year follow-up according to the presence of NYHA class IV vs. ≤III at the admission. 
CV=cardiovascular; NYHA=New York Heart Association 
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Figure 2. Landmark analyses of all-cause death, cardiovascular death and readmission during the 
first 3 months after the procedure (a, b and c) and from 3-month to 4-year (d, e and f) according to 
the presence of NYHA class IV vs. ≤III at the admission. 
CV=cardiovascular; NYHA=New York Heart Association 
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Figure 3. Change in left ventricular ejection fraction (a), systolic pulmonary artery pressure (b) and 
mitral regurgitation (c) at baseline, discharge, 30-day and 1-year follow-up according to the 
presence of NYHA class IV vs. ≤III at the admission. 
LVEF= left ventricular ejection fraction; MR=mitral regurgitation; NYHA= New York Heart 
Association; SPAP= systolic pulmonary artery pressure 
 
Table 1. Baseline characteristics 
Variable NYHA IV (n=271) NYHA ≤ III (n=2,196) 
Age (years) 81 ± 9 82 ± 6 
Men 125 (46%) 942 (43%) 
Body mass index (kg/m2) 25 ± 5 26 ± 5 
STS score  13.1 ± 12.0 7.7 ± 7.5 
<4% 29 (13%) 530 (31%) 
4-8% 64 (29%) 695 (40%) 
>8% 125 (57%) 502 (29%) 
Haemoglobin (g/dl) 11.6 ± 1.7 11.8 ± 1.6 
Creatinine clearance <30mL/min 95 (36%) 418 (20%) 
Hypertension 210 (78%) 1813 (83%) 
Diabetes mellitus 89 (33%) 629 (29%) 
Prior stroke or transient ischaemic attack 32 (16%) 230 (16%) 
Prior myocardial infarction 62 (23%) 346 (16%) 
Chronic obstructive pulmonary disease 58 (21%) 436 (20%) 
Peripheral vascular disease 69 (25%) 488 (22%) 
History of atrial fibrillation  80 (29%) 411 (19%) 
Pure aortic regurgitation 17 (6.3%) 36 (1.7%) 
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Surgical aortic bioprosthesis failure 21 (7.8%) 76 (3.5%) 
Baseline mean gradient (mmHg) 45.0 ± 16.4 50.8 ± 15.4 
Significant aortic regurgitation (≥2+) 125 (50%) 611 (31%) 
Significant mitral regurgitation (≥2+) 152 (61%) 852 (42%) 
Left ventricular ejection fraction (%) 44.7 ± 14.3 52.3 ± 11.7 
Left ventricular end diastolic volume (mL) 117.5 ± 51.2 106.6 ± 45.8 
Left ventricular end systolic volume (mL) 71.1 ± 43.8 53.8 ± 34.0 
Systolic pulmonary pressure >60 mmHg 48 (21%) 168 (9.2%) 
Categorical variables are reported as n (%); continuous variables are reported as mean ± SD 
Table 2. Procedural features 
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Categorical variables are reported as n (%); continuous variables are reported as mean ± SD 
Variable NYHA IV (n=271) NYHA ≤ III (n=2,196) P-value 
General anaesthesia 81 (30%) 453 (21%) 0.001 
Femoral access 220 (81%) 1882 (86%) 0.042 
Evolut R device 66 (24%) 413 (19%) 0.051 
Prosthesis size (mm)   0.004 
23  12 (4.4%) 110 (5%)  
26 98 (36%) 975 (45%)  
29  125 (46%) 921 (42%)  
31  34 (12%) 151 (6.9%)  
34  2 (0.7%) 26 (1.2%)  
Predilation 153 (59%) 1437 (73%) <0.001 
Postdilation 88 (33%) 532 (26%) 0.007 
Device success 254 (94%) 2076 (94%) 0.583 
Procedural success 258 (95%) 2110 (96%) 0.486 
Procedural time (min) 113.4 ± 49.8 105.7 ± 51.4 0.012 
Fluoroscopy time (min) 23.3 ± 13.1 23.8 ± 13.4 0.336 
Contrast media (ml) 175.6 ± 158.8 176.1 ± 99.9 0.155 
Table 3. Acute outcomes 
Variable NYHA IV (n=271) NYHA ≤ III (n=2,196)
In hospital   
All-cause death 21 (7.7%) 74 (3.4%) 
Cardiovascular death 16 (5.9%) 72 (3.3%) 
Myocardial infarction 3 (1.1%) 20 (0.9%) 
Stroke or transient ischaemic attack 6 (2.2%) 34 (1.5%) 
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Categorical variables are reported as n (%); continuous variables are reported as mean ± SD 
 
 
New permanent pacemaker implantation 52 (25%) 398 (21%) 
Acute kidney injury stage 1 38 (17%) 261 (15%) 
Acute kidney injury stage 2 or 3 1 (0.4%) 7 (0.5%) 
Major bleeding 19 (7.2%) 131 (6.2%) 
Life-threatening bleeding 6 (2.3%) 39 (1.8%) 
Vascular complications 36 (13%) 320 (15%) 
Paravalvular leak ≥2+ 39 (15%) 298 (15%) 
Hospital length (days from procedure to discharge) 19.5 ± 0.8 10.1 ± 1.8 
30-day   
All-cause death 24 (8.9%) 110 (5%) 
Cardiovascular death 17 (6.3%) 91 (4.1%) 
Re-hospitalization 3 (1.1%) 25 (1.1%) 
Myocardial infarction 3 (1.1%) 24 (1.1%) 
Stroke or transient ischaemic attack 8 (3%) 57 (2.6%) 
New permanent pacemaker implantation 59 (29%) 508 (27%) 
Paravalvular leak ≥2+ 17 (15%) 131 (13%) 
